LIPELLA PHARMACEUTICALS INC. (LIPO): Nasdaq/NYSE listing notice — Nasdaq grants Lipella continued listing with conditions; compliance deadline April 14, 2025

LIPELLA PHARMACEUTICALS INC.

Received Nasdaq Hearings Panel decision on Jan 10, 2025 granting continued listing subject to interim milestones.
Must file disclosure of equity-increasing transactions and provide fundraising update, income projections by April 14, 2025.
Must demonstrate compliance with minimum stockholders' equity requirement and plan to meet minimum bid price.
Company intends to comply but cautions no assurance; failure could lead to delisting.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

LIPELLA PHARMACEUTICALS INC. received a nasdaq hearing update notice regarding stockholders equity (rules 5550(b)(1), 5550(a)(2)).

Exchange: nasdaq
Notice: hearing update
Deficiency: stockholders equity
Rules: 5550(b)(1), 5550(a)(2)

Exact text from the filing

January 10, 2025, Lipella Pharmaceuticals Inc. (the “Company”) received a decision (the “January Letter”) from the Nasdaq Hearings Panel (the “Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) granting the Company’s requ

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

LIPELLA PHARMACEUTICALS INC. received a nasdaq hearing update notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: hearing update
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

January 10, 2025, Lipella Pharmaceuticals Inc. (the “Company”) received a decision (the “January Letter”) from the Nasdaq Hearings Panel (the “Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) granting the Company’s request for continued listing on the Nasdaq Capital Market, subject to the Company demonstrating compliance with Nasdaq Listing Rule 5550(b)(1) (the “Minimum Stockholders’ Equity Requirement”), including the achievement of interim milestones. Specifically, the Panel granted the Company’s request for continued listing, subject to the following: (i) on or before April 14, 2025, the C

View on SEC.gov

Browse all listing & compliance notices →

LIPELLA PHARMACEUTICALS INC. filing history →

Source: SEC EDGAR

accession 0001753926-25-000078

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.